Mannowetz et al. evaluate the safety and tolerability of the small molecule YCT-529 and show that single doses of up to 180 mg were well tolerated in healthy male subjects of this Phase 1a clinical trial. YCT-529 is developed as a non-hormonal, oral male contraceptive pill with the intention to reduce the risk of unplanned pregnancies.
- Nadja Mannowetz
- Stewart W. McCallum
- Akash Bakshi
